Day: September 4, 2020

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announces that it plans to participate in the following upcoming virtual investor conferences in September 2020:Citi’s 15th Annual BioPharma Virtual Conference – September 08-11, 2020Goldman Sachs 10th Annual Biotech Symposium 2020 – September 11, 2020H.C. Wainwright 22nd Annual Global Investment Conference – September 14-16, 2020About Innate Pharma:Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in...

First commercial test for fully automated high throughput systems to detect and differentiate SARS-CoV-2, influenza A virus and/or influenza B virus with a single sampleAs COVID-19 and influenza infections can hardly be differentiated based on symptoms, healthcare professionals can confidently provide the right diagnosis and best course of treatment for patientsTest for use on high-throughput cobas 6800/8800 Systems will continue to support high volume testing This test is also available in markets accepting the CE markBasel, 04 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the cobas® SARS-CoV-2 & Influenza A/B Test for use on the cobas® 6800/8800 Systems has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). This test is intended for the simultaneous qualitative...

WISeKey to Release First Half 2020 Financial Results on Tuesday, September 8Schedules Conference Call & Webcast for September 8 at 3:00 p.m. CET / 9:00 a.m.Zug, Switzerland – September 4, 2020 – WISeKey International Holding Ltd. (“WISeKey” NASDAQ: WKEY; SIX Swiss Exchange: WIHN), a leading cybersecurity and IoT company, announced today that it will issue its first half 2020 financial results on Tuesday, September 8, 2020.Carlos Moreira, CEO and Peter Ward, CFO will host a conference call on Tuesday, September 8, 2020, at 3:00 p.m. CET / 9:00 a.m. ET to discuss these results, recent business developments and growth initiatives.  A Q&A session will follow the prepared remarks.Interested parties may participate in the call by dialing:                               To access the call, please dial-in approximately five minutes...

Oslo, 4 September 2020Thin Film Electronics ASA (“Thinfilm”), a developer of ultrathin, flexible, and safe energy storage solutions for wearable devices and connected sensors, today released its updated corporate presentation and confirmed its participation in the DNB Nordic TMT Virtual Conference.The company’s September 2020 corporate presentation is enclosed. On 2 September 2020, Thinfilm CEO Kevin Barber presented the company’s strategy at the Nordic TMT Virtual Conference hosted by DNB. Conference details are available at https://dnb.meetmax.com/confThinfilm’s public presentations and webcasts are available on the company’s website at https://www.thinfilmsystems.com/investor-relations/presentations-webcasts/Thinfilm is Energizing Innovation™ with ultrathin, flexible, and safe energy storage solutions...

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announces that it plans to participate in the following upcoming virtual investor conferences in September 2020:Citi’s 15th Annual BioPharma Virtual Conference – September 08-11, 2020Goldman Sachs 10th Annual Biotech Symposium 2020 – September 11, 2020H.C. Wainwright 22nd Annual Global Investment Conference – September 14-16, 2020About Innate Pharma:Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in...

Innate Pharma SA (Euronext Paris : IPH – ISIN: FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui qu’elle sera présente aux événements investisseurs virtuels suivants :Citi’s 15th Annual BioPharma Virtual Conference – Du 8 au 11 septembre 2020Goldman Sachs 10th Annual Biotech Symposium 2020 – Le 11 septembre 2020H.C. Wainwright 22nd Annual Global Investment Conference – Du 14 au 16 septembre 2020À propos d’Innate Pharma:        Innate Pharma S.A. est une société de biotechnologies commerciale spécialisée en immuno-oncologie, dédiée à l’amélioration du traitement des cancers grâce à des anticorps thérapeutiques innovants exploitant le système immunitaire.Le produit commercial d’Innate Pharma, Lumoxiti, pris en licence à AstraZeneca aux États-Unis, en Europe et en Suisse, a été approuvé par la FDA en septembre...

Lassila & Tikanoja plcStock exchange release4 September 2020 8.00 amLassila & Tikanoja’s financial information and AGM in 2021In the year 2021 Lassila & Tikanoja plc will disclose financial information as follows:Financial statements release 2020: 28 January 2021 at 8.00 amInterim Report January – March: 29 April 2021 at 8.00 amHalf-year Report January – June: 27 July 2021 at 8.00 amInterim Report January – September: 26 October 2021 at 8.00 amThe Annual Report that includes the report by the Board of Directors and the financial statements for the year 2020 will be published in February in week 8.The Annual General Meeting is tentatively scheduled for Thursday 18 March 2021. The Board of Directors will decide on the summoning of the meeting at a later date.LASSILA & TIKANOJA PLCEero HautaniemiPresident and CEOAdditional...

Lassila & Tikanoja OyjPörssitiedote4.9.2020 klo 08.00Lassila & Tikanoja Oyj:n taloustiedottaminen ja yhtiökokous vuonna 2021Lassila & Tikanoja Oyj julkistaa vuonna 2021 seuraavat taloudelliset katsaukset:Tilinpäätöstiedote 2020, torstaina 28.1.2021 klo 8.00Osavuosikatsaus tammi – maaliskuu, torstaina 29.4.2021 klo 8.00Puolivuosikatsaus tammi – kesäkuu, tiistaina 27.7.2021 klo 8.00Osavuosikatsaus tammi – syyskuu, tiistaina 26.10.2021 klo 8.00Vuosikertomus, joka sisältää toimintakertomuksen ja tilinpäätöksen vuodelta 2020, julkaistaan helmikuussa viikolla 8.Varsinainen yhtiökokous on suunniteltu pidettäväksi torstaina 18.3.2021. Kokouksen kutsuu koolle yhtiön hallitus erikseen myöhemmin.LASSILA & TIKANOJA OYJEero HautaniemiToimitusjohtajaLisätietoja:toimitusjohtaja Eero Hautaniemi, puh. 010 636 2810talousjohtaja Valtteri...

Marel is pleased to announce an agreement to acquire German food cutting technology provider TREIF Maschinenbau GmbH (“TREIF”). The two companies have a great strategic and cultural fit with complementary product portfolios and geographic presence, creating a strong platform to enhance further growth.About TREIFTREIF, a family-owned business headquartered in Oberlahr, Germany is at the forefront in solutions and services focused on portioning, dicing, slicing and cutting of food. The company was founded in 1948, focusing on cutting solutions for the meat industry, which continues to be its largest segment. With annual revenues of over EUR 80 million, and around 13 million in EBITDA, TREIF has an impressive track record of continuous product innovation and steady growth with 500 employees in facilities in Europe, US, and China. Its long-standing...

Marel tilkynnir undirritun samnings um kaup á þýska félaginu TREIF Maschinenbau GmbH („TREIF“) sem sérhæfir sig í skurðtæknilausnum í matvælaiðnaði. Starfsemi Marel og TREIF fellur vel saman bæði hvað varðar vöruframboð og staðsetningu á mörkuðum, sem skapar sterkan grundvöll fyrir áframhaldandi vöxt.Um TREIFTREIF er fjölskyldufyrirtæki sem á sér langa sögu nýsköpunar og vaxtar, með höfuðstöðvar í Oberlahr í Þýskalandi, og er leiðandi í skurðtæknilausnum og þjónustu (e. portioning, slicing and dicing) í matvælaiðnaði. Félagið var stofnað árið 1948 með áherslu á skurðarlausnir fyrir kjötiðnaðinn, sem enn í dag er þeirra stærsta starfssvið. TREIF er með yfir 80 milljónir evra í árstekjur og um 13 milljónir evra í EBITDA. Starfsmenn félagsins eru um 500 á starfsstöðvum í Evrópu, Bandaríkjunum og Kína. Traustur viðskiptavinahópur TREIF er...